Cardiac dysfunction in the trastuzumab clinical experience

Journal of Clinical Oncology

Volumn 20, Issue 5, 2002, Pages 1156-1157

  Speyer, James ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; DOXORUBICIN DERIVATIVE; PACLITAXEL; RAZOXANE; TRASTUZUMAB; UNCLASSIFIED DRUG;

CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COMORBIDITY; DISEASE ASSOCIATION; DRUG COMPETITION; DRUG MECHANISM; EDITORIAL; HUMAN; INCIDENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 0036498911     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.20.5.1156     Document Type: Editorial

References (7)

1. Cardiac dysfunction in the trastuzumab clinical trials experience
2. Myocyte survival pathways and cardiomyopathy implications for trastuzumab cardiac toxicity
3. Trastuzumab in the treatment of metastatic breast cancer: Anticancer therapy versus cardiotoxicity
4. Risk factors for doxorubicin-induced congestive heart failure
5. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity
6. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study